Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have asked several Wash. DC friends for suggestions, they haven't gotten back to my yet.
Opti
Institutional Ownership and Shareholders
CODX / Co-Diagnostics Inc Institutional Ownership
Co-Diagnostics Inc (US:CODX) has 219 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 10,515,474 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Nuveen Asset Management, LLC, IWM - iShares Russell 2000 ETF, State Street Corp, Geode Capital Management, Llc, Susquehanna International Group, Llp, VEXMX - Vanguard Extended Market Index Fund Investor Shares, and Group One Trading, L.p..
Co-Diagnostics Inc (US:CODX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.
https://fintel.io/so/us/codx
Opti
we need to find a lawyer
Opti
We went thru all this with NEWC, I have 5 years worth of emails from Campo saying "next week" or "you will be very pleased next month"
the stock was de-listed for failure to submit financials. It is still de-listed after 3 years. No conclusion to draw other than that Campo is a bald-faced liar and a crook.
He has your money and couldn't care less about anything else, unless it is planning his next scam.
Opti
watch out.
failure to report can suspend trading; see NEWC
Opti
ADOMANI reports Q4 results
Mar. 31, 2021 4:28 PM ETADOMANI, Inc. (ADOM)By: Shweta Agarwal, SA News Editor
ADOMANI (OTCQB:ADOM): Q4 Net Loss of $1.1M
Revenue of $0.04M (-98.0% Y/Y)
Cash, cash equivalents, and short-term investments of ~$4.1M
Opti
Co-Diagnostics cut to hold at Maxim questioning COVID-19 testing outlook
Mar. 29, 2021 1:02 PM ETCo-Diagnostics, Inc. (CODX)By: Dulan Lokuwithana, SA News Editor7 Comments
The analyst concerns over COVID-19 test makers continue as Maxim Group downgraded Co-Diagnostics (CODX -9.1%) to hold from buy arguing that the stock already reflects whatever the COVID-related benefit as the vaccinations blunt the impact.
The company’s Q4 2020 revenue which was ahead of expectation was 24% higher than the previous quarter, the analysts Jason McCarthy and Michael Okunewitch wrote.
After a steep rally in 2020, the analysts argue that the stock has priced in the COVID-related opportunity and the ensuing revenue growth, which, according to them, has likely peaked.
Citing the current backdrop of the pandemic, ‘we do not expect revenue to reach the level observed in 2020, at least not based on the current COVID environment,’ they conclude removing the stock’s price target.
In February, COVID-19 leveraged test makers slumped after Quidel failed to meet the consensus revenue estimates for Q4 2020.
It has behaved this way several times before. Very frustrating.
Opti
I know that weird feeling; it seems like we are set up every earnings. There is always something strange that happens--an error in the calculations, hyped expectations a month before reporting, changes in the directors--always something off.
With current earnings a normal P/E of ten would have this at $15 right now.
Maybe the lowered expectations for 1st quarter is setting up a beat. At any rate, by May I will have held a year, so long-term gains will help at Tax time, vs short-term rate.
Opti
Eventually the shorts tire and move on to another stock. Hope this is true for CODX. They have sucked enough blood for now.
Opti
agreed
Something is brewing. This is from the earnings call: "And so we're also looking at other ways to partner this in terms of branding and manufacturing, and commercialization. So it will be letting the public know as these types of developments mature. But it is a - it's an incredibly heavy-duty undertaken by the company. It is consuming a great deal of our resource internally and what we're doing from our scientific staff and everything else. So it is a very important and main, you know, sort of long suit for the company at this point."
Opti
How does DE keep his job? We are cruising along in January. Earnings expectations are .43; future PPS set at $30. DE says we are going to crush earnings and the EE is raised to .48; but the stock starts dropping; earnings come it at .43; revised future PPS drops to $20 and we lose 25% PPS in two days. Shareholders should revolt.
Opti
$14.05
Co-Diagnostics, Inc. (CODX) is confirmed to report earnings at approximately 4:00 PM ET on Thursday, March 25, 2021. The consensus earnings estimate is $0.49 per share on revenue of $24.99 million. Investor sentiment going into the company's earnings release has 86% expecting an earnings beat. Consensus estimates are for year-over-year earnings growth of 590.00% with revenue increasing by 22,826.61%. Short interest has decreased by 38.9% since the company's last earnings release while the stock has drifted higher by 18.4% from its open following the earnings release to be 4.3% below its 200 day moving average of $14.68. ... On Wednesday, February 10, 2021 there was some notable buying of 708 contracts of the $3.00 put expiring on Friday, August 20, 2021. Option traders are pricing in a 23.3% move on earnings and the stock has averaged a 13.5% move in recent quarters.
Opti
Earnings on the 25th
Opti
https://www.msn.com/en-us/news/us/admin-frees-10b-for-covid-testing-to-speed-school-reopenings/ar-BB1eGuHB?ocid=msedgdhp
The funding will go out in April and be awarded directly to states, the administration said Wednesday. Because the funding will be allocated proportionally, large states such as California and Texas will receive more than $800 million each, the administration said.
The administration is also designating $2.25 billion for Covid-19 testing to address health disparities among underserved populations and a $150 million to help get Covid treatments to underserved communities.
The testing funds are the latest efforts by the Biden administration to push schools to reopen.
Opti
Co-Diagnostics: A+ Student Faces New Tests
Mar. 12, 2021 10:45 AM ETCo-Diagnostics, Inc. (CODX)3 Likes
Summary
Co-Diagnostics went public in 2017 with a proprietary infectious disease testing technology and a clever strategy.
During its early rollout, Co-Diagnostics' strategy failed to generate noticeable revenues.
As 2020 unfolded, the pandemic both validated Co-Diagnostics' technology and its revenue potential.
Surprisingly, Co-Diagnostics is maintaining its appeal even as the pandemic starts to wind down.
I first became interested in Co-Diagnostics (CODX) because of its outstanding A+ quant grades for value, growth, and profitability on 12/22/20. These grades set it apart from its Healthcare peers; only two others were able to match its report.
Recently I checked back to see how it was faring. As I write on 3/11/21 its report is holding strong, A+'s across all three terrains as shown below:
Co-Diagnostics In this article I will drill down on Co-Diagnostics, explaining why I agree from an operational standpoint with its stellar quant grades. I take an optimistic view of its prospects. Those who have room in their portfolio for a highly speculative micro-cap with good prospects should find that Co-Diagnostics just fills the bill.
https://seekingalpha.com/article/4413467-co-diagnostics-student-faces-new-tests
The Lordstown Motors Mirage: Fake Orders, Undisclosed Production Hurdles, And A Prototype Inferno
(NASDAQ:RIDE)
• Lordstown is an electric vehicle SPAC with no revenue and no sellable product, which we believe has misled investors on both its demand and production capabilities.
• The company has consistently pointed to its book of 100,000 pre-orders as proof of deep demand for its proposed EV truck. Our conversations with former employees, business partners and an extensive document review show that the company’s orders are largely fictitious and used as a prop to raise capital and confer legitimacy.
• For example, Lordstown recently announced a 14,000-truck deal from E Squared Energy, supposedly representing $735 million in sales. E Squared is based out of a small residential apartment in Texas that doesn't operate a vehicle fleet.
• Another 1,000-truck, $52.5 million order comes from a 2-person startup that operates out of a Regus virtual office with a mailing address at a UPS Store. We spoke with the owner who acknowledged it won’t actually order any vehicles, instead describing the “pre-order” as a mere marketing relationship.
• Yet another firm that is supposedly set to buy 500 trucks from Lordstown told us: “…The letters of interest are non-binding. It’s not like you’d obligate yourself to a pre-order or that you would contractually bind yourself to buying this truck. That’s not what they are.”
• Lordstown CEO Steve Burns has called these arrangements “very serious orders”. The actual customer agreements, which we present for the first time today, require no deposit and are non-binding. Many of the supposed customers do not operate fleets nor do many have the means to actually make the stated purchases.
• Former employees and litigation records reveal that in order to raise capital and confer credibility, Steve Burns began paying consultants for every truck pre-order as early as 2016 while he was serving as CEO at Workhorse.
• Later, heading into Lordstown’s eventual go-public transaction in 2020, a small consulting group called Climb2Glory was paid to generate pre-orders. Climb2Glory openly described the purpose behind the pre-order game: “the faster the pre-orders arrived, the greater investors’ confidence would be in the company and the faster funds would flow in.”
• One company rep that committed to buy 40 trucks through Climb2Glory told us: “…I’m not committed to anything, not to buying a single vehicle. I committed to consider buying vehicles. I’d have a lot of questions before I commit to anything."
• Others had similar remarks. “The commitment of that size (15) is totally impossible,” a representative for the City of Ravenna told us about its pre-order. We document numerous other "customers" that disclaim any intent to actually purchase vehicles.
• Multiple former senior employees who have worked with Lordstown Founder & CEO Steve Burns openly described him as a “con man”, or a “PT Barnum” figure. One senior employee told us that, while working with Steve for a couple of years, they saw more questionable and unethical business practices than they had seen in their entire career.
• Despite being allowed to resign from Workhorse, former senior employees described how Burns was pushed out of his old company by the board for wasting R&D money and missing promised deadlines. He then launched Lordstown months later.
• Despite claims that Lordstown will be producing vehicles by September, a former employee explained how the company is experiencing delays and making "drastic" design modifications, putting them an estimated 3-4 years away from production. For example, in mid-January the company “totally switched from a plastic exterior to aluminum,” we were told.
• Despite claims that battery packs would be manufactured in-house, we were told that the equipment is months away from arriving, let alone being put into a production environment. In the meantime, we were told that battery packs are being put together by hand.
• Former employees also shared that the company has completed none of its needed testing or validation, including cold weather testing, durability testing, and Federal Motor Vehicle Safety Standards (FMVSS) testing required by the NHTSA.
• In January 2021, Lordstown’s first street road test resulted in the vehicle bursting into flames 10 minutes into the test drive. We share copies of the 911 call and a police report we received through FOIA requests.
• Lordstown only went public in October 2020, but in that brief time, executives and directors have unloaded ~$28 million in stock. We think it bodes poorly when executives unload stock in a company with no actual product that claims to be on the cusp of mass-production.
• We think investors, workers, and the local community deserve much more transparency on what is going on at Lordstown. We ask 21 questions at the end of our piece that we think the company should answer.
Initial Disclosure: After extensive research, we have taken a short position in shares of Lordstown Motors. This report represents our opinion, and we encourage every reader to do their own due diligence. Please see our full disclaimer at the bottom of the report.
No hope at all. None.
Opti
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test. This is an important tool because these viruses have similar symptoms but require different treatment approaches.
I wonder when they submitted this for FDA approval and how that compares to when CODX submitted. I am trying to guess when we can expect approval.
Opti
CompuNet offers self-ordered COVID-19 PCR and Antigen testing available for purchase without needing a doctor’s order.
PCR Test - $100
The PCR test is considered the gold standard for testing. This test detects RNA (or genetic material) that is specific to the COVID-19 virus and can detect the virus within days of infection, even in those who have no symptoms.
Traveling soon and need to show proof of a negative test? If you are traveling, we will expedite the test to ensure your results are back within 72 hours. When you arrive at the test location, complete the patient information and be sure to check the box for travel, in order to expedite your test results. No appointment is needed at the OnMain location. Feel free to stop by between the hours of 10 a.m. to 5 p.m., Monday through Friday.
White House outlines "bridge" funding to increase Covid-19 testing
From CNN's Betsy Klein
White House Covid-19 response team testing coordinator Carole Johnson announced new steps from the Biden administration to increase testing efforts and capacity across the country, focused on testing for schools and underserved communities, testing supplies, and genomic sequencing as a “bridge” before Congress is able to pass a stimulus package.
“We need to test broadly and rapidly to turn the tide of this pandemic. But we still don’t have enough testing and we don’t have enough testing in all the places it needs to be. Today, we’re taking a critical step along that path,” she said at Wednesday’s virtual Covid briefing.
She outlined a new $1.6 billion federal investment in three key areas:
• $650 million in funding for testing for schools and underserved populations: She said this will “serve only as a pilot” until Congress can pass a relief package. It will create regional coordinating centers that will partner with labs to support schools and underserved committees, including homeless shelters and other places that “don’t have the resources or the bandwidth to build partnerships with academic or commercial testing labs.”
• $815 million for domestic manufacturing of testing supplies: This money will address what Johnson described as a “shortage of critical supplies and raw materials,” including pipette tips, the specialized paper used in the antigen test, and the specialized molded plastics needed to house testing reagents.
• Nearly $200 million toward genome sequencing: The funding will “result in a three-fold increase to the CDC’s genomic sequencing capacity,” bringing the US to 25,000 samples per week, which, she said, will help to quickly identify variants sooner and “better target our efforts to stop the spread.”
Johnson said that these steps are “a significant help in the short term” but are still “far from what’s necessary to meet the needs of testing in communities across the country,” describing the funding as a “bridge until Congress passes the American Rescue Plan.”
“We need to build the capacity to produce these materials, or we'll continue to face shortages that will sidetrack our work in expanding access to testing,” she added.
Opti
News Release Issued: Feb 16, 2021 (9:30am EST)
To view this release online and get more information about Newsroom | Co-Diagnostics, Inc. visit: https://news.codiagnostics.com/2021-02-16-Co-Diagnostics-Inc-to-Present-on-Direct-Saliva-Testing-Technology-at-Molecular-Med-Tri-Con
Co-Diagnostics, Inc. to Present on Direct Saliva Testing Technology at Molecular Med Tri-Con
Company believes direct saliva to play a key role in high throughput, point of care, and at home applications
SALT LAKE CITY, Feb. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct saliva testing for COVID-19 at the 28th Annual International Molecular Medicine Tri-Conference, held virtually on February 16-18, 2021.
Company representatives will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the Company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA). The virtual presentation will be webcast to conference attendees at 4:30 pm EST on Tuesday February 16th, and will include a description of the test technology, its workflow processes, and the engineering process involved in its development, as well as a test demonstration. Co-Diagnostics will also participate in a moderated Q&A panel discussion at 4:50 pm EST the same day with other industry and academic experts in SARS-CoV-2 molecular diagnostic testing.
Co-Diagnostics CEO Dwight Egan remarked "We are honored to introduce this cutting-edge technology to the international molecular diagnostics industry at Tri-Con. The Company believes direct saliva has the potential to greatly improve COVID-19 testing throughput while delivering lower processing costs and increased accessibility of gold-standard PCR diagnostics worldwide, including point-of-care and "at home" applications for businesses, schools, and home settings.
Mr. Egan continued, "This direct saliva test is another illustration of our core belief that affordable, fast, accurate and accessible surveillance and diagnostic solutions should be available everywhere, which includes the use of testing technology that gives individuals the power to know their correct COVID-19 status quickly, and inexpensively. Our direct saliva test technology was developed specifically to address the efficiency demands of high-throughput lab applications as well as the accessibility imperatives of the point-of-care and "at home" markets. As populations around the world go back to the office, as students go back to school, as people again travel and participate in entertainment venues, we believe this direct saliva technology will help ensure "COVID-safe" environments through fast, accurate, affordable and accessible testing solutions."
The Molecular Med Tri-Con is presented by the Cambridge Healthtech Institute and is regarded as the most comprehensive, industry-leading event covering precision medicine and diagnostics today. Parties interested in attending can register at the link found here.
Co-Diagnostics filed for Emergency Use Authorization with the FDA for the Logix Smart SARS-CoV-2 DS. This test has been validated by Co-Diagnostics, but the FDA's independent review of this validation is pending and sales in the US will commence following authorization. The Co-Diagnostics suite of Logix Smart COVID-19 diagnostics are believed to detect all known variants of SARS-CoV-2, including those recently discovered in the UK, South Africa, and Brazil, according to the Company's regulatory bulletin found on the relevant product pages.
If we could get rid of the shorts, this would be a great investment.
Opti
One would think this is being walked down to give shorts a chance to cover, but it is not. It is being shorted; short # is increasing. Now, I hope this doesn't mean that Hindenburg is planning another smash piece just before earnings. Bottom line is that earnings and credibility no longer matter. It is totally a matter of manipulation. If a short hedge fund wants to drive a company pps to zero, they simply do it and there is nothing we can do to stop it. Totally manipulated market. Opti
Closing prices before earnings in August
July 29 $22.08
July 30 $22.96
July 31 $24
Aug 3 $30.80
Volume was the key with over 14 million shares traded on Aug 3.
Note: the previous spike on May 13 had volume of 24 million, followed by a one-day huge drop on volume of 52 million.
On the days leading up to both past spikes the volume was just over 5 million.
Hoping for more of the same next week. look for a day with 5 million shares traded, followed by a big volume spike day. After that spike day, watch very closely. It could drop suddenly (May) or very steady over 30 days (August). Note: it has never held the spike as a new floor. Is this a pattern or a set-up?
Opti
It is a mystery, but I have seen it happen before.
Opti
The sale is real; it is posted on several sites. But the bid/ask is still 6.30/6.31. The sale must have been one of those deals that allows a short to cover.
Opti
After Hours Time (ET) After Hours Price After Hours Share Volume
18:33:12 $4.75 1,070
16:07:53 $6.20 335,000
16:00:54 $6.31 1,070
16:00:39 $6.31 500
16:00:35 $6.31 1,000
I hate to say it, but this is not a long-term hold. It should be; all the fundamentals are great, but the float is simply too small. The hedge funds manipulate this stock to death. Those of us who have held it for a year know this well, We have seen it spike and then drop three times, and all right about the time of earnings. Everything looks great and then we have a garbage hit piece issued by one of the hedge fund "research" teams and the pps collapses. Several of us have posted we will not let this happen again, but beware of the greed when you think it is going to $60 instead of dropping back to $8. If it hits $30 again I will sell and then buy back 2 months later. Great company, but that means nothing in this totally crooked market.
Opti
Many times, posters on this board are pumping in public and selling in private. You are not as smart as you think,
Opti
Four stock race
APT $16.96
SRNE $14.11
INO $14.96
CODX $14.63
I have been following these four stocks for a year. Amazing group.
Opti
I hope they sold 5 million shares at 300 and paid off all their debt.
Opti
And brokers wonder why we hate short-traders so much.
They are EVIL.
Opti
Funny how RH can sell shares they don't have, but can't buy shares they don't have
It means they issued a PR.
opti
They covered and then they shorted again. Who wouldn't when investors cannot sell?
Shorts are EVIL and greedy. The drive the pps to zero and are never satisfied. GREED and EVIL are a dangerous combination.
Opti
Too late, Robin Hood. You showed us your allegiance to the Hedge Funds.
Opti
I admit to being furious. I always hated short sellers, but when the SEC comes to their rescue, that crosses the line. What the market did in response to the Reddit board attack on the Hedge fund shorts (some of which exceeded 100%) is inexcusable. Hedge fund shorters are EVIL; they drive stocks to zero and feast off the carcasses of the dead, and the SEC comes to their rescue when they are squeezed. They don't raise a finger to aid companies or investors when shorts drive companies under, but somehow when the shorts are squeezed that requires action to halt trading and prohibit buying. Plus the boards stop the Reddit posts as "hate speech"
This is an insane world.
Opti